The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing and capacity for a range of medications used to treat symptoms caused by COVID-19 infection. The approved products include ibuprofen tablets, ibuprofen granules, ambroxol hydrochloride sodium chloride injection, compound codeine phosphate solution (II), and acetylcysteine solution for inhalation.
Companies and Production Increase
The NMPA is taking proactive steps to secure the supply of these critical products in light of the current public health pressures in China. Companies involved in the expanded production include Xinhua Pharma, HengDi Pharma, Double-Crane Pharma, Luxembourg Medicine, and Star Pharma. Notably, production capacity for ibuprofen is expected to increase by 14 million tablets per day.
Therapeutic Uses
Ibuprofen tablets and granules are suitable for antipyretic and analgesic effects, providing relief for fever and pain associated with COVID-19. The ambroxol hydrochloride sodium chloride injection, compound codeine phosphate solution (II), and acetylcysteine solution for inhalation are designed to relieve cough and phlegm, common symptoms in patients with COVID-19.
Future Outlook
The NMPA’s approval to expand production underscores the importance of ensuring adequate supplies of essential medications during the ongoing pandemic. By increasing the production capacity of these key drugs, the NMPA aims to meet the heightened demand and support public health efforts. This initiative highlights the regulatory body’s commitment to addressing the challenges posed by COVID-19 and ensuring that patients have access to necessary treatments.-Fineline Info & Tech
